Oppenheimer analyst Jay Olson downgraded Sutro Biopharma (NASDAQ: STRO) from Outperform to Perform.The analyst comments "Sutro Biopharma reported 4Q24 financial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE